氨磺必利治疗精神分裂症阴性症状的疗效与安全性Meta分析

Comparative study on negative symptoms of schizophrenia treated with amisulpride and other second-gen- eration antipsychotics ： a meta-analysis

目的比较氨磺必利与其他第二代抗精神病药物（Second—generationantipsychotics，SGAs）治疗精神分裂症阴性症状的疗效与安全性。方法计算机检索Pubmed、EMbase、CochraneLibrary、万方数据库、CNKI、维普中文期刊数据库（VIP）以及中国学位论文全文数据库，收集1995年1月～2013年3月关于氨磺必利与其他SGAs治疗精神分裂症的随机对照研究（RandomizedControlledTrials，RCTs）。由两位研究者独立进行文献筛选、资料提取和方法学质量评价后，采用RevMan5．1和Stata12．0软件进行Meta分析。结果13篇RCTs满足纳入标准，共包括1814名受试者。Meta分析结果显示：两组之间的PANSS—N比较，均数差为MD=-0．33，95％C／为（-0．87，0．21），差异无统计学意义（Z=1．20，P=0．23）；两组之间的SANS比较，均数差为MD=-0．21，95％CI为（-1．51，1．50），差异无统计学意义（Z=0．31，P=0．76）；氨磺必利组的不良事件发生率少于其他SGAs组。结论氨磺必利对精神分裂症的阴性症状有效，与其他SGAs相当，安全性稍优于其他SGAs。

Objective To compare the efficacy of amisulpride and other SGAs in treating the negative symptoms of Schizophrenia. Methods The randomized controlled trials （ RCTs ） about Schizophrenia treated with amisulpride and other SGAs from Jan 1995 to Mar 2013 were searched in The Pubmed, EMbasc, Cochrane Library, WanFang Data, CNKI and VIP. Two reviewers independently screened the literatures, extracted the data, and evalu- ated the methodological quality. Than meta-analyses were conducted by using RevMan 5. land Stata 12.0 software. Results The totall3 RCTs were included. Among the 1814 patients involved. The results of meta-analyses showed that the score of PANSS-N was no significant differences between two groups （ MD = - 0.33,95% CI ： （ - 0.87, 0.21 ） , Z = 1.20, P = 0.23 ） ; and the score of SANS was no significant differences between two groups （ MD = - 0.21,95 % CI ： （ - 1.51,1.50） , Z = 0.31, P = 0.76 ）. The side effects were more in other SGAs group than those in amisulpride group. Conclusion Amisulpride is as effective as other SGAs for the treatment of schizophre- nia with predominantly negative symptoms, and it has more advantage than other SGAs in safety.